Gilead Sciences Forecast, price target & analysts
Gilead Sciences Target price 2025 - Analyst rating & recommendation
Gilead Sciences Classifications & Recommendation:
Gilead Sciences Price Target
| Target Price | $116.05 |
| Price | $98.16 |
| Potential | 18.22% |
| Number of Estimates | 22 |
| 22 Analysts have issued a price target Gilead Sciences 2026 . The average Gilead Sciences target price is $116.05. This is 18.22% higher than the current stock price. The highest price target is $140.00 42.62% , the lowest is $92.00 6.28% . | |
| A rating was issued by 31 analysts: 19 Analysts recommend Gilead Sciences to buy, 12 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Gilead Sciences stock has an average upside potential 2026 of 18.22% . Most analysts recommend the Gilead Sciences stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2029
23 Analysts have issued a sales forecast Gilead Sciences 2025 . The average Gilead Sciences sales estimate is $28.7b . This is 0.08% lower than the revenue of the last 12 months(TTM). The highest sales forecast is $29.5b 2.66% , the lowest is $28.3b 1.40% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $28.7b | 6.17% |
|---|---|---|
| 2025 | $28.7b | 0.22% |
| 2026 | $29.8b | 3.87% |
| 2027 | $31.3b | 5.17% |
| 2028 | $33.0b | 5.30% |
| 2029 | $34.2b | 3.67% |
11 Analysts have issued an Gilead Sciences EBITDA forecast 2025. The average Gilead Sciences EBITDA estimate is $14.2b . This is 3.75% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $15.9b 16.49% , the lowest is $12.9b 5.40% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $13.4b | 7.96% |
|---|---|---|
| 2025 | $14.2b | 5.69% |
| 2026 | $15.0b | 5.58% |
| 2027 | $15.9b | 6.41% |
| 2028 | $18.1b | 13.46% |
| 2029 | $19.6b | 8.28% |
EBITDA Margin
| 2024 | 46.74% | 1.69% |
|---|---|---|
| 2025 | 49.50% | 5.91% |
| 2026 | 50.32% | 1.66% |
| 2027 | 50.91% | 1.17% |
| 2028 | 54.85% | 7.74% |
| 2029 | 57.29% | 4.45% |
12 Gilead Sciences Analysts have issued a net profit forecast 2025. The average Gilead Sciences net profit estimate is $7.6b . This is 27.84% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $8.6b 44.70% , the lowest is $7.1b 19.54% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $473m | 91.56% |
|---|---|---|
| 2025 | $7.6b | 1,501.41% |
| 2026 | $8.7b | 14.17% |
| 2027 | $9.5b | 9.86% |
| 2028 | $10.4b | 9.05% |
| 2029 | $10.9b | 5.28% |
Net Margin
| 2024 | 1.65% | 92.05% |
|---|---|---|
| 2025 | 26.43% | 1,504.85% |
| 2026 | 29.05% | 9.91% |
| 2027 | 30.35% | 4.48% |
| 2028 | 31.43% | 3.56% |
| 2029 | 31.92% | 1.56% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
12 Analysts have issued a Gilead Sciences forecast for earnings per share. The average Gilead Sciences EPS is $6.09 . This is 27.94% higher than earnings per share in the financial year 2024. The highest EPS forecast is $6.89 44.75% , the lowest is $5.69 19.54% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $0.38 | 91.56% |
|---|---|---|
| 2025 | $6.09 | 1,502.63% |
| 2026 | $6.95 | 14.12% |
| 2027 | $7.63 | 9.78% |
| 2028 | $8.32 | 9.04% |
| 2029 | $8.76 | 5.29% |
P/E ratio
| Current | 20.64 | 88.57% |
|---|---|---|
| 2025 | 16.13 | 21.85% |
| 2026 | 14.13 | 12.40% |
| 2027 | 12.86 | 8.99% |
| 2028 | 11.79 | 8.32% |
| 2029 | 11.20 | 5.00% |
Based on analysts' sales estimates for 2025, the Gilead Sciences stock is valued at an EV/Sales of 4.82 and an P/S ratio of 4.27 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 4.81 | 32.14% |
|---|---|---|
| 2025 | 4.82 | 0.17% |
| 2026 | 4.64 | 3.73% |
| 2027 | 4.41 | 4.92% |
| 2028 | 4.19 | 5.03% |
| 2029 | 4.04 | 3.54% |
P/S ratio
| Current | 4.27 | 44.78% |
|---|---|---|
| 2025 | 4.27 | 0.08% |
| 2026 | 4.11 | 3.73% |
| 2027 | 3.91 | 4.92% |
| 2028 | 3.71 | 5.03% |
| 2029 | 3.58 | 3.54% |
Gilead Sciences...
Current Gilead Sciences Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Oppenheimer |
Outperform
➜
Outperform
|
Unchanged | Apr 25 2025 |
| Needham |
Hold
➜
Hold
|
Unchanged | Apr 25 2025 |
| Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Apr 25 2025 |
| JP Morgan |
Overweight
➜
Overweight
|
Unchanged | Mar 27 2025 |
| Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Mar 11 2025 |
| B of A Securities |
Buy
➜
Buy
|
Unchanged | Mar 05 2025 |
| Wells Fargo |
Overweight
➜
Overweight
|
Unchanged | Mar 05 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Oppenheimer:
Outperform
➜
Outperform
|
Apr 25 2025 |
|
Unchanged
Needham:
Hold
➜
Hold
|
Apr 25 2025 |
|
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Apr 25 2025 |
|
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
Mar 27 2025 |
|
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Mar 11 2025 |
|
Unchanged
B of A Securities:
Buy
➜
Buy
|
Mar 05 2025 |
|
Unchanged
Wells Fargo:
Overweight
➜
Overweight
|
Mar 05 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
